Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of KALA BIO's KPI-012?
KPI-012 is a cell therapy commercialized by KALA BIO, with a leading Phase II program in Persistent Corneal Epithelial Defects....